

# Cedric Poyet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4142748/publications.pdf>

Version: 2024-02-01

79  
papers

1,640  
citations

331259

21  
h-index

344852

36  
g-index

85  
all docs

85  
docs citations

85  
times ranked

3380  
citing authors

#	ARTICLE	IF	CITATIONS
1	Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy. <i>European Urology Focus</i> , 2022, 8, 457-464.	1.6	14
2	Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer. <i>Cancers</i> , 2022, 14, 1135.	1.7	5
3	Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 273.e11-273.e20.	0.8	8
4	Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology "Young Academic Urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 195.e27-195.e35.	0.8	5
5	Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort. <i>European Urology</i> , 2022, 82, 163-169.	0.9	14
6	Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy. <i>Prostate</i> , 2022, 82, 388-396.	1.2	15
7	Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer. <i>Cell Reports Medicine</i> , 2022, 3, 100604.	3.3	7
8	Prospective observational study of the role of the microbiome in BCG responsiveness prediction (SILENT-EMPIRE): a study protocol. <i>BMJ Open</i> , 2022, 12, e061421.	0.8	7
9	Use of MS-GUIDE for identification of protein biomarkers for risk stratification of patients with prostate cancer. <i>Clinical Proteomics</i> , 2022, 19, 9.	1.1	3
10	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. <i>World Journal of Urology</i> , 2021, 39, 1947-1953.	1.2	7
11	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. <i>World Journal of Urology</i> , 2021, 39, 443-451.	1.2	13
12	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 315-324.	1.0	5
13	Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. <i>Prostate</i> , 2021, 81, 286-294.	1.2	4
14	Effectiveness of Flexible Ureterorenoscopy Versus Extracorporeal Shock Wave Lithotripsy for Renal Calculi of 5-15mm: Results of a Randomized Controlled Trial. <i>European Urology Open Science</i> , 2021, 25, 5-10.	0.2	7
15	Alternating Cystoscopy with Bladder EpiCheck® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. <i>Bladder Cancer</i> , 2021, 7, 307-315.	0.2	3
16	Tumor stent for chronic ureteral obstruction: Which are predictors of stent failure?. <i>Journal of Endourology</i> , 2021, , .	1.1	3
17	Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. <i>European Urology Focus</i> , 2020, 6, 1226-1232.	1.6	18
18	Photoselective vaporization of the prostate: study outcomes as a function of risk of bias, conflicts of interest, and industrial sponsorship. <i>World Journal of Urology</i> , 2020, 38, 741-746.	1.2	4

#	ARTICLE	IF	CITATIONS
19	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. <i>Surgical Oncology</i> , 2020, 34, 312-317.	0.8	7
20	Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer – examining the utility of classifying Ta bladder cancer based on size. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 851.e19-851.e25.	0.8	6
21	Convergent network effects along the axis of gene expression during prostate cancer progression. <i>Genome Biology</i> , 2020, 21, 302.	3.8	17
22	Postoperative Chemotherapy Bladder Instillation After Radical Nephroureterectomy: Results of a European Survey from the Young Academic Urologist Urothelial Cancer Group. <i>European Urology Open Science</i> , 2020, 22, 45-50.	0.2	6
23	Dynamic contrast enhancement in prostate MRI as predictor of erectile function and recovery after radical prostatectomy. <i>Aging Male</i> , 2020, 23, 1518-1526.	0.9	1
24	Characterization of Tumor Blood Vasculature Expression of Human Invasive Bladder Cancer by Laser Capture Microdissection and Transcriptional Profiling. <i>American Journal of Pathology</i> , 2020, 190, 1960-1970.	1.9	8
25	Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1. <i>Scientific Reports</i> , 2020, 10, 3808.	1.6	12
26	A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 603.e1-603.e7.	0.8	13
27	External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer. <i>Journal of Urology</i> , 2020, 203, 719-726.	0.2	23
28	Is loss of power output due to laser fiber degradation still an issue during prostate vaporization using the 180W GreenLight XPS laser?. <i>World Journal of Urology</i> , 2019, 37, 181-187.	1.2	3
29	Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 457-467.	1.2	19
30	Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools. <i>BMC Medical Research Methodology</i> , 2019, 19, 191.	1.4	7
31	High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. <i>Molecular Oncology</i> , 2019, 13, 2305-2328.	2.1	100
32	Comparative analysis of mRNA and protein degradation in prostate tissues indicates high stability of proteins. <i>Nature Communications</i> , 2019, 10, 2524.	5.8	35
33	Pure Bipolar Plasma Vaporization of the Prostate: Results from a Prospective 3D Ultrasound Volumetry Study with Clinical Outcome After 3 Years. <i>Journal of Endourology</i> , 2019, 33, 107-112.	1.1	0
34	Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1600-1610.	2.1	24
35	Combined genetic and epigenetic alterations of the <i>TERT</i> promoter affect clinical and biological behavior of bladder cancer. <i>International Journal of Cancer</i> , 2019, 144, 1676-1684.	2.3	57
36	Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 1837-1844.	1.2	16

#	ARTICLE	IF	CITATIONS
37	Alternative transcription of a shorter, non-anti-angiogenic thrombospondin-2 variant in cancer-associated blood vessels. <i>Oncogene</i> , 2018, 37, 2573-2585.	2.6	22
38	Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis. <i>Scientific Reports</i> , 2018, 8, 3477.	1.6	13
39	Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 238.e19-238.e27.	0.8	3
40	Three-Dimensional Texture Analysis with Machine Learning Provides Incremental Predictive Information for Successful Shock Wave Lithotripsy in Patients with Kidney Stones. <i>Journal of Urology</i> , 2018, 200, 829-836.	0.2	38
41	The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 36.	1.0	18
42	Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 364-369.	1.4	23
43	Prevalence and causes of abnormal PSA recovery. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 341-349.	1.4	3
44	Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers. <i>Life Science Alliance</i> , 2018, 1, e201800042.	1.3	51
45	A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. <i>European Urology</i> , 2018, 74, 197-203.	0.9	93
46	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 10284-10293.	0.8	44
47	Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer. <i>Prostate</i> , 2017, 77, 549-556.	1.2	34
48	Detecting circulating tumor DNA in renal cancer: An open challenge. <i>Experimental and Molecular Pathology</i> , 2017, 102, 255-261.	0.9	28
49	The Next Generation of Prostate Cancer Risk Calculators. <i>European Urology</i> , 2017, 72, 897-898.	0.9	0
50	A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients. <i>Scientific Data</i> , 2017, 4, 170014.	2.4	21
51	High expression of insulin receptor on tumour-associated blood vessels in invasive bladder cancer predicts poor overall and progression-free survival. <i>Journal of Pathology</i> , 2017, 242, 193-205.	2.1	24
52	Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 604.e17-604.e24.	0.8	2
53	Prostate volume reduction following pure transurethral bipolar plasma vaporization and conventional transurethral resection of the prostate: a prospective investigation using transrectal 3D ultrasound volumetry. <i>World Journal of Urology</i> , 2017, 35, 429-435.	1.2	4
54	Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer. <i>Oncotarget</i> , 2017, 8, 21871-21883.	0.8	12

#	ARTICLE	IF	CITATIONS
55	Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death. <i>Oncotarget</i> , 2017, 8, 31765-31774.	0.8	15
56	IDLN-MSP: Idioloal normalization of real-time methylation-specific PCR for genetic imbalanced DNA specimens. <i>BioTechniques</i> , 2016, 60, 84-87.	0.8	12
57	Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (<scp>ERSPC</scp>) and Prostate Cancer Prevention Trial (<scp>PCPT</scp>) risk calculators: independent validation and comparison in a contemporary European cohort. <i>BJU International</i> , 2016, 117, 401-408.	1.3	76
58	Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. <i>Scientific Reports</i> , 2016, 6, 24146.	1.6	28
59	Clinical impact of prostate biopsy undergrading in an academic and community setting. <i>World Journal of Urology</i> , 2016, 34, 1481-1490.	1.2	6
60	TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. <i>Cancer Cell</i> , 2016, 29, 846-858.	7.7	228
61	External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC. <i>Journal of Urology</i> , 2016, 196, 1402-1407.	0.2	8
62	Prostate cancer risk calculators: still much work ahead. <i>BJU International</i> , 2016, 118, 670-671.	1.3	0
63	Absorption of irrigation fluid during XPSâ„¢ GreenLight laser vaporization of the prostate: results from a prospective breath ethanol monitoring study. <i>World Journal of Urology</i> , 2016, 34, 1261-1267.	1.2	10
64	Predictive value of low tube voltage and dual-energy CT for successful shock wave lithotripsy: an in vitro study. <i>Urolithiasis</i> , 2016, 44, 271-276.	1.2	10
65	Long-Term Oncologic Outcome of an Initial Series of Laparoscopic Radical Prostatectomy for Clinically Localized Prostate Cancer After a Median Follow-up of 10 Years. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 290-297.	0.9	8
66	Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer. <i>Journal of Pathology Informatics</i> , 2016, 7, 3.	0.8	10
67	Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer. <i>Oncology Letters</i> , 2015, 10, 2753-2760.	0.8	13
68	CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer. <i>Disease Markers</i> , 2015, 2015, 1-8.	0.6	34
69	Acute Abdominal Pain Accompanied by High Creatinine in a Female Patient With Schizophrenia. <i>Urology</i> , 2015, 85, 495-498.	0.5	4
70	pVHL/HIF-Regulated CD70 Expression Is Associated with Infiltration of CD27+ Lymphocytes and Increased Serum Levels of Soluble CD27 in Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 889-898.	3.2	55
71	Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 819-824.	1.0	34
72	Absorption of Irrigation Fluid Occurs Frequently during High Power 532 nm Laser Vaporization of the Prostate. <i>Journal of Urology</i> , 2015, 193, 211-216.	0.2	21

#	ARTICLE	IF	CITATIONS
73	High VEGF-D and Low MMP-2 Serum Levels Predict Nodal-Positive Disease in Invasive Bladder Cancer. <i>Medical Science Monitor</i> , 2015, 21, 2266-2274.	0.5	15
74	Antibody response to BK polyomavirus as a prognostic biomarker and potential therapeutic target in prostate cancer. <i>Oncotarget</i> , 2015, 6, 6459-6469.	0.8	11
75	Unreserved application of epigenetic methods to define differences of DNA methylation between urinary cellular and cell-free DNA. <i>Cancer Biomarkers</i> , 2014, 14, 295-302.	0.8	23
76	Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. <i>BMC Clinical Pathology</i> , 2014, 14, 10.	1.8	61
77	Ablative efficiency of 532-nm laser vaporization compared to transurethral resection of the prostate: results from a prospective three-dimensional ultrasound volumetry study. <i>World Journal of Urology</i> , 2014, 32, 1267-1274.	1.2	6
78	Therapy-resistant nephrolithiasis following renal artery coil embolization. <i>BMC Urology</i> , 2013, 13, 29.	0.6	8
79	Artificial Prostate-Specific Antigen Persistence After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2012, 30, e62-e63.	0.8	11